Table 3.

Comparison of patients whose tumors exhibited temporal genomic heterogeneity (n = 12) and patients whose tumors had completely conserved genomic profiles (n = 33)

	Patients whose tumors had temporal genomic heterogeneity	Patients whose tumors did not have temporal genomic heterogeneity	p value
n	12	33	–
Age at diagnosis [median (Range) in years]	5.8 (0.4–15.7)	6.1 (0.8–18.3)	0.70
Received systemic therapy and/or irradiation between surgeries [n (%)]	6 (50%)	14 (42%)	0.30
WHO grade I [n (%)]a	10 (91%)	24 (73%)	0.66

Statistics were performed using the Wilcoxon Rank-Sum test for differences in age, and using Fischer’s Exact test for differences in the proportions who received interval systemic therapy and/or irradiation and for WHO grade (I versus II) histology, with p-value < 0.05 considered significant

^aExcluding patients with tumors of indeterminate WHO grading [pilomyxoid astrocytoma or low grade neoplasm (unclear if WHO grade I versus II)]